중동 및 아프리카 전체 엑솜 시퀀싱 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

중동 및 아프리카 전체 엑솜 시퀀싱 시장 – 2029년까지의 산업 동향 및 예측

  • Medical Devices
  • Published Report
  • Jun 2022
  • MEA
  • 350 Pages
  • 테이블 수: 97
  • 그림 수: 40

>중동 및 아프리카 전체 엑솜 시퀀싱 시장, 구성 요소(2세대 시퀀싱 및 3세대 시퀀싱), 제품 및 서비스(시스템, 키트 및 서비스), 응용 분야(신약 발견 및 개발, 농업 및 동물 연구, 진단, 개인 맞춤 의료 및 기타), 최종 사용자(제약 및 생명 공학 회사, 학계 및 연구 기관, 병원 및 진료소, 임상 실험실 및 기타), 유통 채널(직거래, 소매 판매 및 기타), 산업 동향 및 2029년까지의 예측.

중동 및 아프리카 전체 엑솜 시퀀싱 시장

시장 분석 및 통찰력

중동 및 아프리카 전체 엑솜 시퀀싱 시장은 2022년에서 2029년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년에서 2029년의 예측 기간 동안 8.2%의 CAGR로 성장하고 있다고 분석합니다. 의료비 지출과 자금 조달의 증가는 예측 기간 동안 시장 수요를 촉진한 주요 원동력입니다.

전체 엑솜 시퀀싱 시장

전체 엑솜 시퀀싱 시장

그러나 전체 엑솜 시퀀싱 치료와 관련된 부작용은 전체 엑솜 시퀀싱 시장의 미래 성장을 방해할 수 있습니다. 주요 시장 참여자의 파트너십 및 인수와 같은 전략적 제휴 채택은 전체 엑솜 시퀀싱 시장 성장의 기회로 작용합니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020

양적 단위

수익은 백만 달러, 가격은 미화로 표시됨

다루는 세그먼트

구성 요소별(2세대 시퀀싱 및 3세대 시퀀싱 ), 제품 및 서비스(시스템, 키트 및 서비스), 응용 프로그램(약물 발견 및 개발, 농업 및 동물 연구, 진단, 개인화 의학 및 기타), 최종 사용자(제약 및 생명 공학 회사, 학계 및 연구 기관, 병원 및 진료소, 임상 실험실 및 기타), 유통 채널(직거래, 소매 판매 및 기타)

적용 국가

사우디 아라비아, 남아프리카, UAE, 이스라엘, 이집트, 기타 중동 및 아프리카

시장 참여자 포함

Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx(Bio-Techne의 일부), FOUNDATION MEDICINE, INC.(F. Hoffmann-La Roche Ltd의 자회사), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta US Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics(PerkinElmer Inc.의 자회사), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc. 등이 있습니다.

전체 엑솜 시퀀싱 시장 정의

Whole exome is a genomic technique for sequencing all of the protein-coding region of genes in a genome. Whole exome sequencing is available to patients who are searching for a unifying diagnosis for multiple medical conditions. A laboratory process that is used to determine the nucleotide sequence primarily of the exonic (or protein-coding) regions of an individual’s genome and related sequences, representing approximately 1% of the complete DNA sequence, also called WES. Whole-exome sequencing is a widely used whole exome sequencing method that involves sequencing the protein-coding regions of the genome. The human exome represents less than 2% of the genome, but contains ~85% of known disease-related variants, making this method a cost-effective alternative to whole-genome sequencing.

Exome sequencing using exome enrichment can efficiently detect coding variants across a wide range of applications, including population genetics, genetic disease and cancer studies. The growth of the global whole exome sequencing market is attributed to the reduction in time and cost for sequencing. With the development of new technologies and cancer cure treatment, the whole exome sequencing market in clinical oncology has huge potential in the coming years.

Middle East & Africa Whole Exome Sequencing Market Dynamics

Drivers

  • Increase in the adoption of next generation sequencing (NGS)

As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors.

NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.

  • Growing usage of targeted sequencing methods

As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors.

NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.

Restraint

  • Less comprehensive coverage of exons

All the exons are not comprehensively captured. The exon of importance may not be included in the current standard annotations of the human genome; and it is merely arduous to cover 100% of the exome with the current WES technology. Consequently, disease-causing variants in these “missed” exons go undetected.

WES has low sensitivity for structural variations, hence detection is limited. Nonetheless some CNVs, including indels and duplications, can be detected by WES, the technical limitation implies that others are likely missed

Opportunity

  • Strategic Initiatives by the key market player

The demand for whole exome sequencing is increasing in the market owing to the increased incidence of genetic disease along with increased geriatric population across the region. Thus, the top market players have implemented the strategy of collaboration with other market players aimed at improving business operations and profitability.

Challenge

  • Ethical and legal issues related to whole exome sequencing

Rapid advances in high throughput genomic technologies and next generation sequencing are making medical genomic research more readily accessible and affordable, including the sequencing of patient and control whole genomes and exomes in order to elucidate genetic factors underlying disease. Progress of high throughput genomic technologies and next generation sequencing (NGS) methods in recent years has changed the scope of human genomic studies. These advances have made it feasible to routinely perform whole exome sequencing (WES) studies.

Due to the large-scale, collaborative nature of studies, ethical and legal issues are of increasing concern and have important implications in Africa. African populations are of unique interest because, despite having the highest levels of genetic diversity, living in a vast array of environmental and cultural settings, as well as suffering from a high burden of disease that could be studied using genomics approaches, they are facing legal issues in WES.

Post COVID-19 Impact on Whole Exome Sequencing Market

COVID-19 has resulted in a substantial upsurge in demand for medical supplies from both healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the whole exome sequencing market.

Recent Development

  • In May, 2022, Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally. This has helped the company to expand its presence.
  • In March, 2022, several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA seeks to educate healthcare providers and other stakeholders about the value of such testing to assure adherence to existing guidelines from professional medical societies, to inform medical management and cascade testing, and to improve clinical outcomes. This has helped company to adhere to guidelines.

중동 및 아프리카 전체 엑솜 시퀀싱 시장 세분화

중동 및 아프리카 전체 엑솜 시퀀싱 시장은 구성 요소, 제품 및 서비스, 애플리케이션, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 세그먼트 간 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 애플리케이션 영역과 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.

요소

  • 2세대 시퀀싱
  • 3세대 시퀀싱

중동 및 아프리카 전체 엑솜 시퀀싱 시장은 구성 요소를 기준으로 2세대 시퀀싱과 3세대 시퀀싱으로 구분됩니다.

제품 및 서비스

  • 시스템
  • 키트
  • 서비스

중동 및 아프리카 전체 엑솜 시퀀싱 시장은 제품과 서비스를 기준으로 시스템, 키트, 서비스로 구분됩니다.

애플리케이션

  • 진단
  • 약물 발견 및 개발
  • 개인맞춤의학
  • 농업 및 동물 연구
  • 기타

중동 및 아프리카 전체 엑솜 시퀀싱 시장은 응용 분야를 기준으로 약물 발견 및 개발, 농업 및 동물 연구, 진단, 개인화 의학 및 기타로 세분화됩니다.

최종 사용자

  • 병원 및 진료소
  • 제약 및 생명공학 회사
  • 학술 및 연구 기관
  • 임상실험실
  • 기타

최종 사용자를 기준으로 중동 및 아프리카 전체 엑솜 시퀀싱 시장은 제약 및 생명 공학 회사, 학술 및 연구 기관, 병원 및 진료소, 임상 실험실 및 기타로 세분화됩니다.

유통 채널

  • 직접 거래
  • 소매 판매
  • 기타

전체 엑솜 시퀀싱 시장

중동 및 아프리카 전체 엑솜 시퀀싱 시장은 유통 채널을 기준으로 직접 거래, 소매 판매 및 기타로 구분됩니다.

전체 엑솜 시퀀싱 시장 국가 수준 분석

엑솜 시퀀싱 시장 전체를 분석하고, 구성 요소, 제품 및 서비스, 응용 프로그램, 최종 사용자 및 유통 채널별로 시장 규모 정보를 제공합니다.

전체 엑솜 시퀀싱 시장 보고서에서 다루는 국가는 사우디아라비아, 남아프리카공화국, UAE, 이스라엘, 이집트, 기타 중동 및 아프리카 국가입니다.

남아프리카 공화국은 예측, 치료를 위한 차세대 시퀀싱 방법의 수용 증가로 인해 예측 기간 동안 우위를 점할 것입니다. 남아프리카 공화국은 암과 같은 다양한 만성 질환의 모니터링으로 인해 성장할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

전체 엑솜 시퀀싱 시장은 또한 모든 국가의 의료 산업 성장에 대한 자세한 시장 분석을 제공합니다. 게다가, 의료 서비스와 치료, 규제 시나리오의 영향, 전체 엑솜 시퀀싱 시장에 대한 추세 매개변수에 대한 자세한 정보를 제공합니다.

경쟁 환경 및 전체 엑솜 시퀀싱 시장 점유율 분석

전체 엑솜 시퀀싱 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선이 있습니다. 제공된 위의 데이터 포인트는 전체 엑솜 시퀀싱 시장과 관련된 회사의 초점에만 관련이 있습니다.

전체 엑솜 시퀀싱 시장을 다루는 주요 기업으로는 Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx(Bio-Techne의 일부), FOUNDATION MEDICINE, INC.(F. Hoffmann-La Roche Ltd의 자회사), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta US Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics(PerkinElmer Inc.의 자회사), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc. 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 아시아 태평양 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 INDUSTRIAL INSIGHTS:

4.4 CONCLUSION

5 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS

6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING

6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING

6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION

6.2 RESTRAINTS

6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS

6.2.2 CYBER SECURITY CONCERNS IN GENOMICS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER

6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS

6.4 CHALLENGES

6.4.1 LACK OF SKILLED PROFESSIONALS

6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING

7 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT

7.1 OVERVIEW

7.2 SECOND-GENERATION SEQUENCING

7.2.1 SEQUENCING BY SYNTHESIS (SBS)

7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL)

7.3 THIRD-GENERATION SEQUENCING

8 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE

8.1 OVERVIEW

8.2 SYSTEMS

8.2.1 HISEQ SERIES

8.2.1.1 HISEQ 2500

8.2.1.2 HISEQ 1500

8.2.2 MISEQ SERIES

8.2.3 ION TORRENT PLATFORMS

8.2.3.1 ION PROTON

8.2.3.2 ION PGM

8.2.4 OTHERS

8.3 KITS

8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS

8.3.2 LIBRARY PREPARATION KITS

8.3.3 TARGET ENRICHMENT KITS

8.3.4 OTHERS

8.4 SERVICES

8.4.1 SEQUENCING SERVICES

8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES

8.4.3 OTHERS

9 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 DRUG DISCOVERY AND DEVELOPMENT

9.3 AGRICULTURE & ANIMAL RESEARCH

9.4 DIAGNOSTICS

9.5 PERSONALIZED MEDICINE

9.6 OTHERS

10 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER

10.1 OVERVIEW

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.3 ACADEMIC & RESEARCH INSTITUTES

10.4 HOSPITALS AND CLINICS

10.5 CLINICAL LABORATORIES

10.6 OTHERS

11 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TRADE

11.3 RETAIL SALES

11.4 OTHERS

12 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY REGION

12.1 MIDDLE EAST AND AFRICA

12.1.1 SOUTH AFRICA

12.1.2 SAUDI ARABIA

12.1.3 U.A.E

12.1.4 ISRAEL

12.1.5 EGYPT

12.1.6 REST OF MIDDLE EAST AND AFRICA

13 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

14 COMPANY PROFILE

14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.)

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COM PANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 MERCK KGAA

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COM PANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 EXODX (A PART OF BIO-TECHNE)

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COM PANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 THERMO FISHER SCIENTIFIC INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COM PANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COM PANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 AZENTA US, INC.

14.6.1 COMPANY SNAPSHOT

14.6.2 PRODUCT PORTFOLIO

14.6.3 RECENT DEVELOPMENTS

14.7 BECKMAN COULTER, INC

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENTS

14.8 BIONEER CORPORATION

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENTS

14.9 CD GENOMICS

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENTS

14.1 CEGAT GMBH

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 EUROFINS SCIENTIFIC

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENTS

14.12 GENEDX, LLC

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 GENEFIRST LIMITED.

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENTS

14.14 ILLUMINA, INC

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENTS

14.15 INTEGRATED DNA TECHNOLOGIES, INC.

14.15.1 COMPANY SNAPSHOT

14.15.2 PRODUCT PORTFOLIO

14.15.3 RECENT DEVELOPMENTS

14.16 MERIDIAN BIOSCIENCE, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

14.17 PSOMAGEN

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENTS

14.18 QIAGEN

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENTS

14.19 SOPHIA GENETICS

14.19.1 COMPANY SNAPSHOT

14.19.2 REVENUE ANALYSIS

14.19.3 PRODUCT PORTFOLIO

14.19.4 RECENT DEVELOPMENTS

14.2 TWIST BIOSCIENCE

14.20.1 COMPANY SNAPSHOT

14.20.2 REVENUE ANALYSIS

14.20.3 PRODUCT PORTFOLIO

14.20.4 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

표 목록

TABLE 1 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA THIRD-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA DRUG DISCOVERY AND DEVELOPMENT IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA AGRICULTURE & ANIMAL RESEARCH IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA DIAGNOSTICS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA PERSONALIZED MEDICINE IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA ACADEMIC & RESEARCH INSTITUTES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA HOSPITALS AND CLINICS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA CLINICAL LABORATORIES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA DIRECT TRADE IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA RETAIL SALES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 43 SOUTH AFRICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 44 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 45 SOUTH AFRICA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 46 SOUTH AFRICA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 47 SOUTH AFRICA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 48 SOUTH AFRICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 49 SOUTH AFRICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 50 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 51 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 54 SAUDI ARABIA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 55 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 56 SAUDI ARABIA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 57 SAUDI ARABIA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 58 SAUDI ARABIA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 59 SAUDI ARABIA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 60 SAUDI ARABIA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 61 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 62 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 63 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 64 U.A.E WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 65 U.A.E SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 66 U.A.E WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 67 U.A.E SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 68 U.A.E HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 69 U.A.E ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 70 U.A.E KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 71 U.A.E SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 72 U.A.E WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 U.A.E WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 74 U.A.E WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 75 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 76 ISRAEL SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 77 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 78 ISRAEL SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 79 ISRAEL HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 80 ISRAEL ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 81 ISRAEL KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 82 ISRAEL SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 83 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 84 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 85 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 86 EGYPT WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 87 EGYPT SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 88 EGYPT WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 89 EGYPT SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 90 EGYPT HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 91 EGYPT ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 92 EGYPT KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 93 EGYPT SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 94 EGYPT WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 95 EGYPT WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 96 EGYPT WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 97 REST OF MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASE IN USE OF WES TECHNOLOGY FOR NEW SCIENTIFIC APPLICATIONS AND INCREASING THE PREFERENCE OF WES OVER WHOLE-GENOME SEQUENCING IS ITS LOW-COST SEQUENCING CAPABILITY IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 THE INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET IN 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET

FIGURE 15 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2021

FIGURE 16 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2022-2029 (USD MILLION)

FIGURE 17 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, CAGR (2022-2029)

FIGURE 18 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, LIFELINE CURVE

FIGURE 19 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2021

FIGURE 20 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2022-2029 (USD MILLION)

FIGURE 21 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, CAGR (2022-2029)

FIGURE 22 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, LIFELINE CURVE

FIGURE 23 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2021

FIGURE 24 LOBAL WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 25 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 26 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 27 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY END USER, 2021

FIGURE 28 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 29 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY END USER, CAGR (2022-2029)

FIGURE 30 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY END USER, LIFELINE CURVE

FIGURE 31 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 32 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 33 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 34 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 35 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: SNAPSHOT (2021)

FIGURE 36 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021)

FIGURE 37 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022 & 2029)

FIGURE 38 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021 & 2029)

FIGURE 39 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT (2022-2029)

FIGURE 40 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

South Africa is the dominating region of the Middle East and Africa Whole Exome Sequencing Market.
The Middle East and Africa Whole Exome Sequencing Market growth rate will be 8.2% by 2029.
The Increase in the adoption of next generation sequencing (NGS) and Growing usage of targeted sequencing methods are the growth drivers of the Middle East and Africa Whole Exome Sequencing Market.
The component, product and service, application, end user and distribution channel are the factors on which the Middle East and Africa Whole Exome Sequencing Market research is based.
The major companies in the Middle East and Africa Whole Exome Sequencing Market are Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc.